Skip to main content

Humacyte, Inc.

corporate_fare Company Profile

Humacyte, Inc.

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed HUMA - Latest Insights

HUMA
Apr 28, 2026, 4:52 PM EDT
Filing Type: DEF 14A
Importance Score:
8
HUMA
Apr 24, 2026, 8:09 AM EDT
Filing Type: 8-K
Importance Score:
7
HUMA
Apr 21, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
HUMA
Apr 17, 2026, 4:30 PM EDT
Filing Type: PRE 14A
Importance Score:
8
HUMA
Mar 27, 2026, 4:45 PM EDT
Filing Type: 10-K
Importance Score:
9
HUMA
Mar 27, 2026, 7:00 AM EDT
Source: Reuters
Importance Score:
8
HUMA
Mar 19, 2026, 4:33 PM EDT
Filing Type: 8-K
Importance Score:
8
HUMA
Mar 19, 2026, 4:26 PM EDT
Filing Type: 424B3
Importance Score:
9
HUMA
Mar 19, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
HUMA
Mar 19, 2026, 8:25 AM EDT
Filing Type: 8-K
Importance Score:
8
HUMA
Mar 17, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7